Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
FAIL · Does not pass the screen
44.40 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 20:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price44.40 USD at the 6 Nov 2026 close
Our value readUndervalued vs our fair value, as of 6 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.39, read 2026-11-07
Ethical does not pass the values gate
Price44.40 USD
Fair value52.31
Ethical score70.0/100
Value readUndervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-11-01Read Markup45.06-1.5% to today Distribution gives way to Markup after a 61% rise in 3 weeks
2026-10-11Read Distribution27.99+58.6% to today Accumulation gives way to Distribution
2026-10-02Read Accumulation27.99+58.6% to today ✓Markdown gives way to Accumulation after a 60% slide in 4 weeks
2026-09-04Read Markdown70.49-37.0% to today ✓Markup gives way to Markdown with results news in the headlines
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Liquidia Corporation holds its Markup at $44.40. The statistical read favours the buyers, held for 27 days.
As held on the ledger · 2026-11-06
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 27 days
Price at the screen
$44.40
Valuation
34.09 trailing · 21.66 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.41
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
60.36%
Below 33%
Interest-bearing debt is 60.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
74.64%
Below 49%
Money owed to the company is 74.6% of assets, above the 49% limit.
Fail
Revenue purity
4.18%
Below 5%
Only 4.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Liquidia's business is in a permissible area, but its interest-bearing debt is about 60% of the company, well over the ~33% line, so it does not pass on the financial screens. Its receivables are also high.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when LQDA's ethical verdict changes
Today LQDA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 6 Nov 2026: it trades at roughly a 15% discount to our $52.31 fair value, 1,842.70% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 15.1% discount to the base estimate.
Where our models see it going: fair-value estimate $52.31, with a range of $36.09 to $60.15, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Rare lung drug launch sparks explosive revenue jump
A patient with pulmonary hypertension gets a new inhaled option that bypasses hospital pumps and daily infusions. Liquidia has turned that need into a product now driving revenue growth above 4000 percent, with an 8 percent profit margin and 28 percent return on equity. The ethical screen clears, yet our opportunity rating stays at none because the market price already sits near our fair value.
Forward earnings sit at 14.3 times, which looks reasonable next to the growth, but eight analysts still cluster around a 70 dollar median target well below the current quote. The business remains a single-product story in a narrow rare-disease niche, so any slip in uptake or reimbursement quickly resets the numbers.
Unknown competitive defences and typical biotech execution risks sit alongside currency and regulatory swings common to specialty drugs. The setup rewards close watching rather than immediate commitment. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
LQDA trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-08Markup$44.40+0.0%Entry 21
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 21% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 337%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (8 analysts) rates it none, with a mean price target of $65. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-07Markup$44.40-0.2%Entry 20
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 21% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 337%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (8 analysts) rates it none, with a mean price target of $65. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-06Markup$44.49-6.1%Entry 19
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 6.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 21% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 337%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (8 analysts) rates it none, with a mean price target of $65. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-05Markup$47.38+5.1%Entry 18
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 21% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 337%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (8 analysts) rates it none, with a mean price target of $65. Insiders have been net sellers over the past quarter. Since the last review it its composite score eased. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markup$45.06+0.0%Entry 17
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 21% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 337%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (8 analysts) rates it none, with a mean price target of $65. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markup$45.06+0.0%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 21% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 337%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (8 analysts) rates it none, with a mean price target of $65. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markup · changed$45.06+5.7%Entry 15
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 21% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 337%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (8 analysts) rates it none, with a mean price target of $65. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Distribution$42.65+0.0%Entry 14
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 21% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 337%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (8 analysts) rates it none, with a mean price target of $65. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Distribution$42.65+0.0%Entry 13
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 21% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 337%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (8 analysts) rates it none, with a mean price target of $65. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Distribution$42.65+17.3%Entry 12
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 17.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 21% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 337%. Our forward projection puts the odds of a 10% gain over the next month near 45%. The street (8 analysts) rates it none, with a mean price target of $65. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
